ArticleChemistry & biodiversity2025
Phytochemical Profile and Anticancer Activity of Achillea conferta Leaf Extracts: Insights Into Antioxidant Properties.
Article in Chemistry & biodiversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explores the phytochemical composition and biological potential of extracts from Achillea conferta leaves, specifically hydroethanolic extract (HE), total flavonoid extract (TFE), and glycoside flavonoid extract (GFE). Phytochemical screening of HE revealed significant concentrations of phenolic compounds, flavonoids, and tannins, quantified as 48.36 µg GAE/mL extract, 32.40 µg QE/mL extract, and 4.85 µg TAE/mL extract, respectively. High-performance liquid chromatography identified key flavonoids in TFE and GFE, including catechin, epigallocatechin, hesperidin, myricetin, rutin, isorhamnetin, and luteolin. Antioxidant activities were assessed using assays for reactive oxygen species (ROS), total peroxides, and free radical scavenging (2,2-diphenyl-1-picrylhydrazyl). GFE demonstrated the highest ROS concentration at 269 µM/g extract. The antiproliferative effects on breast, esophageal, and large intestine cancer cell lines were evaluated, with GFE showing greater efficacy than TFE in all tested cell lines, highlighting the therapeutic potential of A. conferta extracts. These findings highlight the medicinal potential of A. conferta as a natural source of antioxidants and anticancer agents. However, further research is necessary to explore detailed mechanistic pathways and the in vivo efficacy of these extracts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.